Kimia Farma Tbk.

kaef

Overview

KAEF Overview

PT Kimia Farma Tbk is an Indonesia-based company, which is engaged in producing, distributing, and marketing chemical industry product, active pharmaceutical ingredients (API) and high function chemicals (HFC). Its segments include Manufacturing, Distribution, Retail, and Other. The Manufacturing segment includes chemical and pharmaceutical manufacturing, research and development, and manufacturing marketing and marketing of quinine and essential oils; manufacturing and marketing of active pharmaceutical ingredients and HFC, and manufacturing and marketing of pharmaceutical products. The distribution segment is engaged in distribution of pharmaceutical products to domestic market and to the international market, including Saudi Arabia, the United States, Netherlands, the United Kingdom, China, Malaysia, and several other countries. The Retail segment is engaged in the sale of medicines and pharmaceutical products directly to customers.

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: KAEF

Main
Market Cap.
IDR 5.04Trillion

~$320.56M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

KAEF Valuation Metrics

895

IDR

Closing Price on 2024-04-05

Price to Equity

-30.26

P/E

At -30.26x P/E TTM, KAEF.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Book

P/B

Not available

No P/B data available for KAEF.JK.

Price to Sales

0.49

P/S

At 0.49x P/S TTM, KAEF.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Valuing Kimia Farma Tbk. based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Kimia Farma Tbk. relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
-13.38x
Price/Forward Earnings
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
-
PEG Ratio
0.04x

Analyst Ratings

No analyst ratings available yet.

Valuation Recap of KAEF stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of -30.26x is below the ID market average of 8.22x and is trading at a discount to peers in the Pharmaceuticals & Health Care Research sector (8.87x). In fact, less than 25% of its peers trade at a lower P/E ratio than KAEF.●●●
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.49x is similar to the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of KAEF's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. KAEF's P/CF ratio of -13.38x is considered healthy by analysts.●●
Max 2

Peers

KAEF Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
KAEFKimia Farma Tbk.5.04T8.99T 10.19T -0.17T -30.26
Competitiveness Recap of KAEF stock
WeightNotesScore
High
At a market cap of IDR 5,036.79 billion, KAEF.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of -30.26, KAEF.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -23.08 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of -30.26, KAEF.JK is trading at a lower PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 8.87). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.
Max 2
Medium
At a revenue of IDR 10.19 trillion, KAEF.JK ranks 4 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of -IDR 0.17 trillion, KAEF.JK ranks 10 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of KAEF

Growth Forecasts

KAEF 2024 Revenue Growth
-5.8%
KAEF 2024 EPS Growth
0.0%
Sector Revenue Growth
-1.2%
Pharmaceuticals & Health Care Research
Indonesia Market Growth
+12.0%
IDX overall growth
Pharmaceuticals & Health Care Research Sector Revenue Growth '24
+11.1%
Healthcare Sector Revenue Growth '24
+17.1%

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are shrinking at a projected rate of -1.18% against the IDX average of +12.0%.

Pharmaceuticals & Health Care Research sector overview

KAEF Earnings & Revenue Forecast

All values in IDR billion

Future growth prospect of KAEF
WeightNotesScore
High
KAEF's projected growth rate of -1.18% is below the ID market average of 11.98%.●●●
Max 3
High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 11.14% in 2024. This number is higher than the previous year 2023's growth rate of 2.48%. This bodes well for KAEF's revenue growth prospects in the next 2 years. ●●
Max 3
Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 2.56% in 2024. This number is higher than the previous year 2023's EPS growth of -8.71%. false
Max 3
Medium
KAEF and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for KAEF's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

David Utama15.2 years
Lina Sari
Director
Hadi Kardoko
Director
Dharma Syahputra
Director
Jasmine Karsono
Director
Chairani Harahap
Director
NamePositionShares%
No data is available for KAEF at the moment.
Expressed in millions IDR, unless otherwise stated

Ownership

KAEF Ownership

Others
4.38%
Insiders
95.46%
Institutions
0.16%
NameNumber of SharesOwnership (%)Value
Pt Bio Farma (Persero)4,999,999,99989.894,475.00B
Public (Scripless)562,386,00010.11503.34B

Largest Institutional Buy

No data is available for KAEF at the moment.

Largest Institutional Sell

JOM Rahastoyhtiö Oy/ Fund Management Ltd
Sold 31-12-2023
-4,909,800 shares

Institutional Transactions

Tracking institutional transactions buying / selling of KAEF stock